Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Unknown 1

Sponsor Class

NETWORK 3NIH 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 3168Uterine Cervical Neoplasms 2191Endometrial Neoplasms 1334Breast Neoplasms 819Fallopian Tube Neoplasms 808Carcinoma, Ovarian Epithelial 772Neoplasms 540Colorectal Neoplasms 439Carcinoma, Non-Small-Cell Lung 420Uterine Cervical Dysplasia 376Pancreatic Neoplasms 363Stomach Neoplasms 354Prostatic Neoplasms 318Lung Neoplasms 315Melanoma 289Uterine Neoplasms 239Peritoneal Neoplasms 238Neoplasm Metastasis 238Vulvar Neoplasms 229Urinary Bladder Neoplasms 225Esophageal Neoplasms 225Head and Neck Neoplasms 222Sarcoma 219Carcinoma, Renal Cell 214Recurrence 213Colonic Neoplasms 210Papillomavirus Infections 206Triple Negative Breast Neoplasms 191Squamous Cell Carcinoma of Head and Neck 177Vaginal Neoplasms 147

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrent Uterine Corpus Carcinoma × Gynecologic × Clear all
NCT01164735 2024-08-14

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

GOG Foundation

Completed
169 enrolled
Gynecologic

Recurrent Uterine Corpus Carcinoma

NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled
Gynecologic

Recurrent Uterine Corpus Carcinoma

NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

GOG Foundation

Phase 2 Unknown
67 enrolled 9 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡